Harvard Bioscience (HBIO) 10-Q 7 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Oct. 31, 2023
Document Information [Line Items]
Entity Central Index Key	0001123494
Entity Registrant Name	HARVARD BIOSCIENCE INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-33957
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3306140
Entity Address, Address Line One	84 October Hill Road
Entity Address, City or Town	Holliston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01746
City Area Code	508
Local Phone Number	893-8999
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HBIO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		42,688,246

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,340	$ 4,508
Accounts receivable, net	14,983	16,705
Inventories	25,818	26,439
Other current assets	4,345	3,472
Total current assets	50,486	51,124
Property, plant and equipment, net	3,358	3,366
Operating lease right-of-use assets	5,061	5,816
Goodwill	56,222	56,260
Intangible assets, net	17,095	21,014
Other long-term assets	7,513	7,780
Total assets	139,735	145,360
Current liabilities:
Current portion of long-term debt	3,470	3,811
Current portion of operating lease liabilities	2,125	2,135
Accounts payable	6,269	6,447
Deferred revenue	4,005	3,370
Other current liabilities	8,336	7,486
Total current liabilities	24,205	23,249
Long-term debt, net	35,273	43,013
Deferred tax liability	661	590
Operating lease liabilities	4,418	5,282
Other long-term liabilities	892	1,006
Total liabilities	65,449	73,140
Commitments and contingencies - Note 13
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 42,688,246 shares issued and outstanding at September 30, 2023; 42,081,707 shares issued and outstanding at December 31, 2022	457	454
Additional paid-in-capital	232,896	229,008
Accumulated deficit	(143,787)	(142,190)
Accumulated other comprehensive loss	(15,280)	(15,052)
Total stockholders' equity	74,286	72,220
Total liabilities and stockholders' equity	$ 139,735	$ 145,360

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	80,000,000	80,000,000
Common stock, shares issued (in shares)	42,688,246	42,081,707
Common stock, shares outstanding (in shares)	42,688,246	42,081,707

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 25,363	$ 26,922	$ 84,097	$ 84,908
Cost of revenues	10,636	14,750	34,351	39,922
Gross profit	14,727	12,172	49,746	44,986
Sales and marketing expenses	5,732	5,819	17,888	19,093
General and administrative expenses	5,807	6,324	17,494	18,630
Research and development expenses	2,760	2,763	8,614	9,480
Amortization of intangible assets	1,361	1,572	4,138	4,492
Litigation settlement - Note 14	0	(544)	0	(233)
Total operating expenses	15,660	15,934	48,134	51,462
Operating (loss) income	(933)	(3,762)	1,612	(6,476)
Other income (expense):
Unrealized gain (loss) on equity securities - Note 14	1,208	0	(373)	0
Interest expense	(882)	(749)	(2,797)	(1,648)
Other income (expense), net	45	(179)	105	(163)
Total other income (expense)	371	(928)	(3,065)	(1,811)
Loss before income taxes	(562)	(4,690)	(1,453)	(8,287)
Income tax expense (benefit)	677	(1,285)	144	(437)
Net loss	$ (1,239)	$ (3,405)	$ (1,597)	$ (7,850)
Loss per share:
Basic loss per share (in dollars per share)	$ (0.03)	$ (0.08)	$ (0.04)	$ (0.19)
Weighted-average common shares:
Basic and diluted (in shares)	42,688	41,637	42,345	41,353

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net loss	$ (1,239)	$ (3,405)	$ (1,597)	$ (7,850)
Other comprehensive (loss) income:
Foreign currency translation adjustments	(1,343)	(2,936)	(354)	(6,152)
Derivatives qualifying as hedges, net of tax	117	0	126	0
Other comprehensive loss	(1,226)	(2,936)	(228)	(6,152)
Comprehensive loss	$ (2,465)	$ (6,341)	$ (1,825)	$ (14,002)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2021	41,143,000
Balance at Dec. 31, 2021	$ 452	$ 225,650	$ (132,674)	$ (10,027)	$ 83,401
Stock-based compensation expense	0	3,401	0	0	3,401
Net loss	0	0	(7,850)	0	(7,850)
Other comprehensive loss	$ 0	0	0	(6,152)	(6,152)
Stock option exercises (in shares)	40,000
Stock option exercises	$ 1	106	0	0	107
Vesting of restricted stock units (in shares)	628,000
Vesting of restricted stock units	$ 0	0	0	0	0
Shares withheld for taxes (in shares)	(232,000)
Shares withheld for taxes	$ 0	(1,167)	0	0	(1,167)
Stock purchase plan (in shares)	78,000
Stock purchase plan	$ 0	239	0	0	239
Balance (in shares) at Sep. 30, 2022	41,657,000
Balance at Sep. 30, 2022	$ 453	228,229	(140,524)	(16,179)	71,979
Balance (in shares) at Jun. 30, 2022	41,500,000
Balance at Jun. 30, 2022	$ 453	227,413	(137,119)	(13,243)	77,504
Stock-based compensation expense	0	1,139	0	0	1,139
Net loss	0	0	(3,405)	0	(3,405)
Other comprehensive loss	$ 0	0	0	(2,936)	(2,936)
Stock option exercises (in shares)	24,000
Stock option exercises	$ 0	64	0	0	64
Vesting of restricted stock units (in shares)	233,000
Vesting of restricted stock units	$ 0	0	0	0	0
Shares withheld for taxes (in shares)	(100,000)
Shares withheld for taxes	$ 0	(387)	0	0	(387)
Balance (in shares) at Sep. 30, 2022	41,657,000
Balance at Sep. 30, 2022	$ 453	228,229	(140,524)	(16,179)	71,979
Balance (in shares) at Dec. 31, 2022	42,082,000
Balance at Dec. 31, 2022	$ 454	229,008	(142,190)	(15,052)	72,220
Stock-based compensation expense	0	3,618	0	0	3,618
Net loss	0	0	(1,597)	0	(1,597)
Other comprehensive loss	$ 0	0	0	(228)	$ (228)
Stock option exercises (in shares)	214,000				213,644
Stock option exercises	$ 3	506	0	0	$ 509
Vesting of restricted stock units (in shares)	413,000
Vesting of restricted stock units	$ 0	0	0	0	0
Shares withheld for taxes (in shares)	(112,000)
Shares withheld for taxes	$ 0	(451)	0	0	(451)
Stock purchase plan (in shares)	91,000
Stock purchase plan	$ 0	215	0	0	215
Balance (in shares) at Sep. 30, 2023	42,688,000
Balance at Sep. 30, 2023	$ 457	232,896	(143,787)	(15,280)	74,286
Balance (in shares) at Jun. 30, 2023	42,688,000
Balance at Jun. 30, 2023	$ 457	231,533	(142,548)	(14,054)	75,388
Stock-based compensation expense	0	1,363	0	0	1,363
Net loss	0	0	(1,239)	0	(1,239)
Other comprehensive loss	$ 0	0	0	(1,226)	(1,226)
Balance (in shares) at Sep. 30, 2023	42,688,000
Balance at Sep. 30, 2023	$ 457	$ 232,896	$ (143,787)	$ (15,280)	$ 74,286

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (1,597)	$ (7,850)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	1,083	1,122
Amortization of intangible assets	4,138	4,492
Amortization of deferred financing costs	210	210
Stock-based compensation expense	3,618	3,401
Deferred income taxes and other	92	(160)
Unrealized loss on equity securities - Note 14	373	0
Convertible Preferred Stock received in Biostage settlement - Note 14	0	(3,900)
Gain on sale of product line	(403)	0
Changes in operating assets and liabilities:
Accounts receivable	1,751	6,060
Inventories	173	(329)
Other assets	(50)	(811)
Accounts payable and other current liabilities	695	(2,379)
Deferred revenue, change	635	(551)
Other liabilities	(993)	(832)
Net cash provided by (used in) operating activities	9,725	(1,527)
Cash flows from investing activities:
Additions to property, plant and equipment	(958)	(1,355)
Acquisition of intangible assets	(292)	0
Proceeds from sale of product line	512	0
Net cash used in investing activities	(738)	(1,355)
Cash flows from financing activities:
Borrowing from revolving line of credit	3,500	7,800
Repayment of revolving line of credit	(8,450)	(4,650)
Repayment of term debt	(3,341)	(2,436)
Proceeds from exercise of stock options and employee stock purchase plan	724	346
Taxes paid related to net share settlement of equity awards	(451)	(1,167)
Net cash used in financing activities	(8,018)	(107)
Effect of exchange rate changes on cash	(137)	312
Increase (decrease) in cash and cash equivalents	832	(2,677)
Cash and cash equivalents at beginning of period	4,508	7,821
Cash and cash equivalents at end of period	5,340	5,144
Supplemental disclosures of cash flow information:
Cash paid for interest	3,006	1,529
Cash paid for income taxes, net of refunds	$ 168	$ 493

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies, and Risks and Uncertainties	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation and Summary of Significant Accounting Policies, and Risks and Uncertainties Basis of Presentation and Summary of Significant Accounting Policies The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”) as of September 30, 2023 three nine September 30, 2023 2022, December 31, 2022 not not 10 December 31, 2022. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2023, three nine September 30, 2023 2022, three nine September 30, 2023, not The accounting policies underlying the accompanying unaudited consolidated financial statements are set forth in Note 2 10 December 31, 2022. no three nine September 30, 2023. Marketable Equity Securities Equity securities traded in active markets are marked to market at each balance sheet date based on their prices as quoted on the relevant stock exchange. Fair value mark-to-market adjustments are recorded as non-operating gains (losses) in the consolidated statement of operations. The Company’s investments in marketable equity securities are classified in the consolidated balance sheet based on the nature of the securities and their availability for use in current operations. Risks and Uncertainties The global supply chain has experienced significant disruptions over the last few years due to electronic component and labor shortages and other macroeconomic factors which have emerged since the onset of COVID- 19. may may

Note 2 - Recently Issued Accoun

Note 2 - Recently Issued Accounting Pronouncements	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	2. Recently Adopted Accounting Pronouncements In January 2017, 2017 04, Intangibles Goodwill and Other (Topic 350 2017 04” 2 2016 13 January 1, 2023 no 2017 04. In September 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” may 2016 13 2016 13 January 1, 2023,

Note 3 - Goodwill and Intangibl

Note 3 - Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	3. Goodwill and Intangible Assets The change in the carrying amount of goodwill for the nine September 30, 2023 (in thousands) Carrying amount at December 31, 2022 $ 56,260 Effect of change in currency translation (38 ) Carrying amount at September 30, 2023 $ 56,222 Intangible assets at September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 (in thousands) Average Accumulated Accumulated Amortizable intangible assets: Life* Gross Amortization Net Gross Amortization Net Distribution agreements/customer relationships 6 $ 16,017 $ (9,467 ) $ 6,550 $ 16,124 $ (8,727 ) $ 7,397 Existing technology & software development 2 37,490 (28,851 ) 8,639 37,549 (26,482 ) 11,067 Trade names and patents 3 7,484 (5,774 ) 1,710 7,523 (5,197 ) 2,326 Total amortizable intangible assets $ 60,991 $ (44,092 ) $ 16,899 $ 61,196 $ (40,406 ) $ 20,790 Indefinite-lived intangible assets: 196 224 Total intangible assets $ 17,095 $ 21,014 *Weighted average life in years as of September 30, 2023 Intangible asset amortization expense was $1.4 million and $1.6 million for the three September 30, 2023 2022, nine September 30, 2023 2022, five September 30, 2023, (in thousands) 2023 (remainder of the year) $ 1,383 2024 5,234 2025 4,019 2026 2,358 2027 1,261 2028 1,308 Thereafter 1,336 Total $ 16,899

Note 4 - Balance Sheet Informat

Note 4 - Balance Sheet Information	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	4. Balance Sheet Information The following tables provide details of selected balance sheet items as of the periods indicated: Inventories: (in thousands) September 30, 2023 December 31, 2022 Finished goods $ 6,047 $ 5,223 Work in process 4,642 3,776 Raw materials 15,129 17,440 Total $ 25,818 $ 26,439 Other Current Liabilities: (in thousands) September 30, 2023 December 31, 2022 Compensation $ 3,373 $ 3,476 Customer credits 3,111 2,368 Professional fees 599 392 Warranty costs 308 268 Other 945 982 Total $ 8,336 $ 7,486

Note 5 - Restructuring and Othe

Note 5 - Restructuring and Other Exit Costs	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	5. Restructuring and Other Exit Costs On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities, and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes restructuring-type activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420 Exit or Disposal Cost Obligations During the three September 30, 2022,

Note 6 - Leases

Note 6 - Leases	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. Leases The Company has noncancelable operating leases for offices, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030. The components of lease expense for the three nine September 30, 2023 2022, Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Operating lease cost $ 491 $ 486 $ 1,517 $ 1,483 Short-term lease cost 19 58 150 180 Sublease income (25 ) (25 ) (76 ) (76 ) Total lease cost $ 485 $ 519 $ 1,591 $ 1,587 Supplemental cash flow information related to the Company's operating leases is as follows: Nine Months Ended September 30, (in thousands) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities $ 1,764 $ 1,759 Right-of-use assets obtained in exchange for lease obligations 277 248 Supplemental balance sheet information related to the Company’s operating leases are as follows: (in thousands) September 30, 2023 December 31, 2022 Operating lease right-of-use assets $ 5,061 $ 5,816 Current portion, operating lease liabilities $ 2,125 $ 2,135 Operating lease liabilities, long-term 4,418 5,282 Total operating lease liabilities $ 6,543 $ 7,417 Weighted average remaining lease term (years) 5.8 6.2 Weighted average discount rate 9.4 % 9.4 % Future minimum lease payments for operating leases, with initial terms in excess of one September 30, 2023, Year Ending December 31, (in thousands) 2023 (remainder of the year) $ 550 2024 1,909 2025 1,155 2026 1,052 2027 1,046 Thereafter 2,963 Total lease payments 8,675 Less imputed interest (2,132 ) Total operating lease liabilities $ 6,543

Note 7 - Long-term Debt

Note 7 - Long-term Debt	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Long-Term Debt [Text Block]	7. Long-Term Debt As of September 30, 2023 December 31, 2022, (in thousands) September 30, 2023 December 31, 2022 Long-term debt: Term loan $ 31,473 $ 34,814 Revolving line 7,900 12,850 Less: unamortized deferred financing costs (630 ) (840 ) Total debt 38,743 46,824 Less: current portion of long-term debt (3,750 ) (4,091 ) Current unamortized deferred financing costs 280 280 Long-term debt $ 35,273 $ 43,013 In December, 2020, March 27, 2023, none December 22, 2025. September 30, 2023 Borrowings under the amended Credit Facility will, at the option of the Company, bear interest at either (i) a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) for an interest period of one, two, three six no The effective interest rate on the Company borrowings for the three September 30, 2023 2022, nine September 30, 2023 2022, September 30, 2023, The term loan amortizes in quarterly installments of $0.75 million for the quarter ended December 31, 2023 seven ninety may December 31, 2022, March 31, 2023. The Credit Agreement, as amended, includes customary affirmative, negative, and financial covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, incur liens, make investments, sell assets and pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement, as amended, also includes customary events of default. In April, 2022, 14 November, 2022, September 30, 2023.

Note 8 - Derivatives

Note 8 - Derivatives	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	8. Derivatives The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not By using derivative financial instruments to hedge exposure to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may On February 28, 2023, September 30, 2023 December 22, 2025. not 7, The following table presents the notional amount and fair value of the Company’s derivative instrument as of September 30, 2023: (in thousands) September 30, 2023 Derivatives instruments Balance sheet classification Notional Amount Fair Value (a) Interest rate swap Other long term assets $ 28,847 $ 126 (a) See Note 9 The following table summarizes the effect of derivatives designated as cash flow hedging instruments for the three nine September 30, 2023: Three Months Ended Nine Months Ended Derivatives qualifying as hedges, net of tax September 30, 2023 September 30, 2023 Amount of gain recognized in OCI on derivatives (effective portion) $ 163 $ 198 Amounts reclassified from accumulated other comprehensive loss to interest expense (46 ) (72 ) Total $ 117 $ 126

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. Fair Value Measurements The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis: Fair Value as of September 30, 2023 Assets Level 1 Level 2 Level 3 Total Equity securities - common stock $ 3,788 $ - $ - $ 3,788 Interest rate swap agreements - 126 - 126 The Company uses the market approach technique to value its financial assets and liabilities. The Company’s financial assets and liabilities carried at fair value include, when applicable, investments in common stock and derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s investment in common stock of Harvard Apparatus Regenerative Technologies (“ HART 14

Note 10 - Capital Stock and Sto

Note 10 - Capital Stock and Stock-based Compensation	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Shareholders' Equity and Share-Based Payments [Text Block]	10. Capital Stock and Stock-Based Compensation Stock-Based Payment Awards Stock-based awards consist of stock options, time-based restricted stock units, market condition restricted stock units, and shares issued under the Company’s employee stock purchase plan. Activity under the Company’s equity incentive plans for the nine September 30, 2023 Weighted Market Average Condition Stock Exercise Restricted Grant Date Restricted Grant Date Options Price Stock Units Fair Value Stock Units Fair Value Balance at December 31, 2022 1,238,776 $ 3.15 1,093,801 $ 3.94 646,235 $ 4.51 Granted - - 1,306,445 2.82 558,958 2.61 Exercised (213,644 ) 2.38 - - - - Vested (RSUs) - - (295,531 ) 2.97 (115,976 ) 2.98 Cancelled/Forfeited (101,065 ) 2.47 (86,440 ) 3.90 (87,138 ) 4.64 Balance at September 30, 2023 924,067 3.37 2,018,275 3.36 1,002,079 3.62 Stock-based compensation expense for the three nine September 30, 2023 2022 Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenues $ 58 $ - $ 222 $ 88 Sales and marketing expenses 193 147 533 493 General and administrative expenses 1,012 919 2,585 2,633 Research and development expenses 100 73 278 187 Total stock-based compensation expenses $ 1,363 $ 1,139 $ 3,618 $ 3,401 As of September 30, 2023, not not three nine September 30, 2023. The weighted average estimated fair value of the market condition restricted stock awards that were granted during the nine September 30, 2023 Volatility 56.8 % Risk-free interest rate 4.6 % Correlation coefficient 41.7 % Dividend yield - % Earnings (Loss) Per Share Basic earnings (loss) per share (EPS) is calculated by dividing net income (loss) by the number of weighted average shares of common stock outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options and restricted stock units into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted EPS consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2023 2022 2023 2022 Net loss available to common stockholders $ (1,239 ) $ (3,405 ) $ (1,597 ) $ (7,850 ) Weighted average shares outstanding - basic 42,688 41,637 42,345 41,353 Dilutive effect of equity awards - - - - Weighted average shares outstanding - diluted 42,688 41,637 42,345 41,353 Basic loss per share $ (0.03 ) $ (0.08 ) $ (0.04 ) $ (0.19 ) Diluted loss per share $ (0.03 ) $ (0.08 ) $ (0.04 ) $ (0.19 ) Shares excluded from diluted loss per share due to their anti-dilutive effect 3,952 3,594 3,847 3,676

Note 11 - Revenues

Note 11 - Revenues	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	11. Revenues The following tables represent a disaggregation of revenue from contracts with customers for the three nine September 30, 2023 2022: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Instruments, equipment, software and accessories $ 23,500 $ 25,705 $ 79,261 $ 81,008 Service, maintenance and warranty contracts 1,863 1,217 4,836 3,900 Total revenues $ 25,363 $ 26,922 $ 84,097 $ 84,908 The following tables represent a disaggregation of revenue by geographic destination for the three nine September 30, 2023 2022: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 United States $ 12,017 $ 11,511 $ 36,655 $ 38,278 Europe 7,063 7,344 23,836 22,361 Greater China 3,489 4,497 13,824 11,624 Rest of the world 2,794 3,570 9,782 12,645 Total revenues $ 25,363 $ 26,922 $ 84,097 $ 84,908 Concentrations No 10% three nine September 30, 2023 2022. September 30, 2023 December 21, 2022, no 10% Contract Liabilities The following tables provide details of contract liabilities as of the periods indicated: (in thousands) September 30, 2023 December 31, 2022 Change % Change Service contracts $ 2,234 $ 1,530 $ 704 46 % Customer advances 1,771 1,840 (69 ) -4 % Total deferred revenue $ 4,005 $ 3,370 $ 635 19 % The overall increase in contract liabilities was primarily due to receipt of payments under service and warranty contracts. During the three September 30, 2023 2022, December 31, 2022 2021, nine September 30, 2023 2022, December 31, 2022 2021, Allowance for Expected Credit Losses on Receivables The allowance for expected credit losses on receivables is used to present accounts receivable, net at an amount that represents the Company’s estimate of the related transaction price recognized as revenue. The allowance represents an estimate of expected credit losses over the lifetime of the receivables, even if the loss is considered remote, and reflects expected recoveries of amounts previously written-off. The Company estimates the allowance on the basis of specifically identified receivables that are evaluated individually for impairment and an analysis of the remaining receivables determined by reference to past default experience. The Company considers the need to adjust historical information to reflect the extent to which current conditions and reasonable forecasts are expected to differ from the conditions that existed for the historical period considered. Losses on receivables have not Management judgments are used to determine when to charge off uncollectible trade accounts receivable. The Company bases these judgments on the age of the receivable, credit quality of the customer, current economic conditions, and other factors that may not Activity in the allowance for expected losses on receivables is as follows: Nine Months Ended September 30, (in thousands) 2023 2022 Balance, beginning of period $ 191 $ 136 Provision for bad debts 9 103 Charge-offs and other (56 ) (60 ) Balance, end of period $ 144 $ 179

Note 12 - Income Tax

Note 12 - Income Tax	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Tax Income tax expense (benefit) was $0.7 million and $(1.3) million for the three September 30, 2023 2022, nine September 30, 2023 2022, three September 30, 2023 2022, nine September 30, 2023 2022, The difference between the Company’s effective tax rates in 2023 three nine September 30, 2023 2022, The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which the Company operates and the development of tax planning strategies during the year. In addition, as a global commercial enterprise, the Company’s tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingent Liabilities	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and Contingent Liabilities On April 27, 2022, 14, The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not not not one In addition, the Company has entered into indemnification agreements with its directors. It is not not September 30, 2023. The Company is subject to unclaimed property laws in the ordinary course of its business. State escheat laws generally require entities to report and remit abandoned and unclaimed property to the state. Failure to timely report and remit the property can result in assessments that could include interest and penalties, in addition to the payment of the escheat liability itself. The Company is currently undergoing unclaimed property audits conducted in various states. Based on the current stage of the audits, the Company has not September 30, 2023.

Note 14 - Litigation Settlement

Note 14 - Litigation Settlement	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	14. Litigation Settlement On April 14, 2017, 2013, third one two third 2012 2013. On April 27, 2022, not During the nine September 30, 2022, ● During the three March 31, 2022, December 31, 2021, ● During the three June 30, 2022, June 10, 2022, ● During the three September 30, 2022, As of December 31, 2022, 321, Investment Securities December 31, 2022, no no On April 6, 2023, On July 20, 2023, As of September 30, 2023, three nine September 30, 2023, The Company determines the fair value of its HART common stock based on the closing price as quoted on the OTCQB Marketplace at the reporting date. Due to HART’s limited operating history, its overall financial condition and the limited trading volumes and liquidity of its common stock, the value of the Company’s investment in this common stock could fluctuate considerably or become worthless.

Note 15 - Product Line Disposit

Note 15 - Product Line Disposition	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	15. Product Line Disposition On February 17, 2023, nine September 30, 2023. nine September 30, 2023, three nine September 30, 2022, not

Note 16 - Financial Statement R

Note 16 - Financial Statement Reclassifications	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Error Correction [Text Block]	16 . Financial Statement Reclassifications During the three September 30, 2023, December 31, 2022 2021. December 31, 2022 2021, no December 31, 2022 2021, December 31, 2022, 2021. no no 10 September 30, 2023, 10 December 31, 2023

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Summary of Significant Accounting Policies The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”) as of September 30, 2023 three nine September 30, 2023 2022, December 31, 2022 not not 10 December 31, 2022. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2023, three nine September 30, 2023 2022, three nine September 30, 2023, not The accounting policies underlying the accompanying unaudited consolidated financial statements are set forth in Note 2 10 December 31, 2022. no three nine September 30, 2023.
Marketable Securities, Policy [Policy Text Block]	Marketable Equity Securities Equity securities traded in active markets are marked to market at each balance sheet date based on their prices as quoted on the relevant stock exchange. Fair value mark-to-market adjustments are recorded as non-operating gains (losses) in the consolidated statement of operations. The Company’s investments in marketable equity securities are classified in the consolidated balance sheet based on the nature of the securities and their availability for use in current operations.
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The global supply chain has experienced significant disruptions over the last few years due to electronic component and labor shortages and other macroeconomic factors which have emerged since the onset of COVID- 19. may may

Note 3 - Goodwill and Intangi_2

Note 3 - Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Goodwill [Table Text Block]	(in thousands) Carrying amount at December 31, 2022 $ 56,260 Effect of change in currency translation (38 ) Carrying amount at September 30, 2023 $ 56,222
Schedule of Intangible Assets and Goodwill [Table Text Block]	September 30, 2023 December 31, 2022 (in thousands) Average Accumulated Accumulated Amortizable intangible assets: Life* Gross Amortization Net Gross Amortization Net Distribution agreements/customer relationships 6 $ 16,017 $ (9,467 ) $ 6,550 $ 16,124 $ (8,727 ) $ 7,397 Existing technology & software development 2 37,490 (28,851 ) 8,639 37,549 (26,482 ) 11,067 Trade names and patents 3 7,484 (5,774 ) 1,710 7,523 (5,197 ) 2,326 Total amortizable intangible assets $ 60,991 $ (44,092 ) $ 16,899 $ 61,196 $ (40,406 ) $ 20,790 Indefinite-lived intangible assets: 196 224 Total intangible assets $ 17,095 $ 21,014
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(in thousands) 2023 (remainder of the year) $ 1,383 2024 5,234 2025 4,019 2026 2,358 2027 1,261 2028 1,308 Thereafter 1,336 Total $ 16,899

Note 4 - Balance Sheet Inform_2

Note 4 - Balance Sheet Information (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Inventories: (in thousands) September 30, 2023 December 31, 2022 Finished goods $ 6,047 $ 5,223 Work in process 4,642 3,776 Raw materials 15,129 17,440 Total $ 25,818 $ 26,439
Other Current Liabilities [Table Text Block]	Other Current Liabilities: (in thousands) September 30, 2023 December 31, 2022 Compensation $ 3,373 $ 3,476 Customer credits 3,111 2,368 Professional fees 599 392 Warranty costs 308 268 Other 945 982 Total $ 8,336 $ 7,486

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Operating lease cost $ 491 $ 486 $ 1,517 $ 1,483 Short-term lease cost 19 58 150 180 Sublease income (25 ) (25 ) (76 ) (76 ) Total lease cost $ 485 $ 519 $ 1,591 $ 1,587
Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]	Nine Months Ended September 30, (in thousands) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities $ 1,764 $ 1,759 Right-of-use assets obtained in exchange for lease obligations 277 248
Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]	(in thousands) September 30, 2023 December 31, 2022 Operating lease right-of-use assets $ 5,061 $ 5,816 Current portion, operating lease liabilities $ 2,125 $ 2,135 Operating lease liabilities, long-term 4,418 5,282 Total operating lease liabilities $ 6,543 $ 7,417 Weighted average remaining lease term (years) 5.8 6.2 Weighted average discount rate 9.4 % 9.4 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Year Ending December 31, (in thousands) 2023 (remainder of the year) $ 550 2024 1,909 2025 1,155 2026 1,052 2027 1,046 Thereafter 2,963 Total lease payments 8,675 Less imputed interest (2,132 ) Total operating lease liabilities $ 6,543

Note 7 - Long-term Debt (Tables

Note 7 - Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Debt [Table Text Block]	(in thousands) September 30, 2023 December 31, 2022 Long-term debt: Term loan $ 31,473 $ 34,814 Revolving line 7,900 12,850 Less: unamortized deferred financing costs (630 ) (840 ) Total debt 38,743 46,824 Less: current portion of long-term debt (3,750 ) (4,091 ) Current unamortized deferred financing costs 280 280 Long-term debt $ 35,273 $ 43,013

Note 8 - Derivatives (Tables)

Note 8 - Derivatives (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	(in thousands) September 30, 2023 Derivatives instruments Balance sheet classification Notional Amount Fair Value (a) Interest rate swap Other long term assets $ 28,847 $ 126
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Three Months Ended Nine Months Ended Derivatives qualifying as hedges, net of tax September 30, 2023 September 30, 2023 Amount of gain recognized in OCI on derivatives (effective portion) $ 163 $ 198 Amounts reclassified from accumulated other comprehensive loss to interest expense (46 ) (72 ) Total $ 117 $ 126

Note 9 - Fair Value Measureme_2

Note 9 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value as of September 30, 2023 Assets Level 1 Level 2 Level 3 Total Equity securities - common stock $ 3,788 $ - $ - $ 3,788 Interest rate swap agreements - 126 - 126

Note 10 - Capital Stock and S_2

Note 10 - Capital Stock and Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block]	Weighted Market Average Condition Stock Exercise Restricted Grant Date Restricted Grant Date Options Price Stock Units Fair Value Stock Units Fair Value Balance at December 31, 2022 1,238,776 $ 3.15 1,093,801 $ 3.94 646,235 $ 4.51 Granted - - 1,306,445 2.82 558,958 2.61 Exercised (213,644 ) 2.38 - - - - Vested (RSUs) - - (295,531 ) 2.97 (115,976 ) 2.98 Cancelled/Forfeited (101,065 ) 2.47 (86,440 ) 3.90 (87,138 ) 4.64 Balance at September 30, 2023 924,067 3.37 2,018,275 3.36 1,002,079 3.62
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenues $ 58 $ - $ 222 $ 88 Sales and marketing expenses 193 147 533 493 General and administrative expenses 1,012 919 2,585 2,633 Research and development expenses 100 73 278 187 Total stock-based compensation expenses $ 1,363 $ 1,139 $ 3,618 $ 3,401
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2023 2022 2023 2022 Net loss available to common stockholders $ (1,239 ) $ (3,405 ) $ (1,597 ) $ (7,850 ) Weighted average shares outstanding - basic 42,688 41,637 42,345 41,353 Dilutive effect of equity awards - - - - Weighted average shares outstanding - diluted 42,688 41,637 42,345 41,353 Basic loss per share $ (0.03 ) $ (0.08 ) $ (0.04 ) $ (0.19 ) Diluted loss per share $ (0.03 ) $ (0.08 ) $ (0.04 ) $ (0.19 ) Shares excluded from diluted loss per share due to their anti-dilutive effect 3,952 3,594 3,847 3,676
Black Scholes Option Pricing Model [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Volatility 56.8 % Risk-free interest rate 4.6 % Correlation coefficient 41.7 % Dividend yield - %

Note 11 - Revenues (Tables)

Note 11 - Revenues (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Instruments, equipment, software and accessories $ 23,500 $ 25,705 $ 79,261 $ 81,008 Service, maintenance and warranty contracts 1,863 1,217 4,836 3,900 Total revenues $ 25,363 $ 26,922 $ 84,097 $ 84,908
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 United States $ 12,017 $ 11,511 $ 36,655 $ 38,278 Europe 7,063 7,344 23,836 22,361 Greater China 3,489 4,497 13,824 11,624 Rest of the world 2,794 3,570 9,782 12,645 Total revenues $ 25,363 $ 26,922 $ 84,097 $ 84,908
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	(in thousands) September 30, 2023 December 31, 2022 Change % Change Service contracts $ 2,234 $ 1,530 $ 704 46 % Customer advances 1,771 1,840 (69 ) -4 % Total deferred revenue $ 4,005 $ 3,370 $ 635 19 %
Schedule of Product Warranty Liability [Table Text Block]	Nine Months Ended September 30, (in thousands) 2023 2022 Balance, beginning of period $ 191 $ 136 Provision for bad debts 9 103 Charge-offs and other (56 ) (60 ) Balance, end of period $ 144 $ 179

Note 3 - Goodwill and Intangi_3

Note 3 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Amortization of Intangible Assets	$ 1,361	$ 1,572	$ 4,138	$ 4,492

Note 3 - Goodwill and Intangi_4

Note 3 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Carrying amount at December 31, 2022	$ 56,260
Effect of change in currency translation	(38)
Carrying amount at September 30, 2023	$ 56,222

Note 3 - Goodwill and Intangi_5

Note 3 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets, Gross		$ 60,991	$ 61,196
Total amortizable intangible assets		(44,092)	(40,406)
Finite-Lived Intangible Assets, Net		16,899	20,790
Indefinite-lived intangible assets:		196	224
Total intangible assets, Net		$ 17,095	21,014
Distribution Agreements/Customer Relationships [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	6 years
Finite-Lived Intangible Assets, Gross		$ 16,017	16,124
Total amortizable intangible assets		(9,467)	(8,727)
Finite-Lived Intangible Assets, Net		$ 6,550	7,397
Existing Technology and Software Development [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)		2 years
Finite-Lived Intangible Assets, Gross		$ 37,490	37,549
Total amortizable intangible assets		(28,851)	(26,482)
Finite-Lived Intangible Assets, Net		$ 8,639	11,067
Trade Names and Patents [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	3 years
Finite-Lived Intangible Assets, Gross		$ 7,484	7,523
Total amortizable intangible assets		(5,774)	(5,197)
Finite-Lived Intangible Assets, Net		$ 1,710	$ 2,326
[1]Weighted average life in years as of September 30, 2022

Note 3 - Goodwill and Intangi_6

Note 3 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
2023 (remainder of the year)	$ 1,383
2024	5,234
2025	4,019
2026	2,358
2027	1,261
2028	1,308
Thereafter	1,336
Total	$ 16,899	$ 20,790

Note 4 - Balance Sheet Inform_3

Note 4 - Balance Sheet Information - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finished goods	$ 6,047	$ 5,223
Work in process	4,642	3,776
Raw materials	15,129	17,440
Total	$ 25,818	$ 26,439

Note 4 - Balance Sheet Inform_4

Note 4 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Compensation	$ 3,373	$ 3,476
Customer credits	3,111	2,368
Professional fees	599	392
Warranty costs	308	268
Other	945	982
Total	$ 8,336	$ 7,486

Note 5 - Restructuring and Ot_2

Note 5 - Restructuring and Other Exit Costs (Details Textual) $ in Millions	3 Months Ended
	Sep. 30, 2022 USD ($)
Inventory Write-down	$ 1.3
Severance Costs	$ 0.6

Note 6 - Leases - Lease Expense

Note 6 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating lease cost	$ 491	$ 486	$ 1,517	$ 1,483
Short-term lease cost	19	58	150	180
Sublease income	(25)	(25)	(76)	(76)
Total lease cost	$ 485	$ 519	$ 1,591	$ 1,587

Note 6 - Leases - Supplemental

Note 6 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities	$ 1,764	$ 1,759
Right-of-use assets obtained in exchange for lease obligations	$ 277	$ 248

Note 6 - Leases - Supplementa_2

Note 6 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Operating lease right-of-use assets	$ 5,061	$ 5,816
Current portion, operating lease liabilities	2,125	2,135
Operating lease liabilities, long-term	4,418	5,282
Total operating lease liabilities	$ 6,543	$ 7,417
Weighted average remaining lease term (years) (Year)	5 years 9 months 18 days	6 years 2 months 12 days
Weighted average discount rate	9.40%	9.40%

Note 6 - Leases - Future Minimu

Note 6 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
2023 (remainder of the year)	$ 550
2024	1,909
2025	1,155
2026	1,052
2027	1,046
Thereafter	2,963
Total lease payments	8,675
Less imputed interest	(2,132)
Total operating lease liabilities	$ 6,543	$ 7,417

Note 7 - Long-term Debt (Detail

Note 7 - Long-term Debt (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 22, 2020
Debt Issuance Costs, Net, Total	$ 630		$ 630			$ 840
The Credit Agreement [Member]
Debt Issuance Costs, Net, Total							$ 1,400
Line of Credit Facility, Interest Rate During Period	8.30%	5.80%	8.20%	4.30%
Line of Credit Facility, Interest Rate at Period End	7.70%		7.70%
Debt Instrument Quarterly Payment Next Eight Years					$ 750
Debt Instrument, Quarterly Payment, Thereafter					$ 1,000
Percentage of Consolidated Excess Cash Flow					50%
Debt Instrument, Current Maturities, Excess Cash Flow Sweep						1,100
The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member]
Debt Instrument, Interest Rate, State Floor Percentage	0.50%		0.50%
The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate			3.25%
The Credit Agreement [Member] | Base Rate [Member]
Debt Instrument, Interest Rate, State Floor Percentage	1%		1%
The Credit Agreement [Member] | The ABR Loan [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate			1.50%
The Credit Agreement [Member] | The ABR Loan [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate			3%
The Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Remaining Borrowing Capacity	$ 13,000		$ 13,000
Term Loan [Member]
Long-term Debt, Gross	$ 31,473		$ 31,473			$ 34,814
The SOFR Loan and Pricing Grid Credit Agreement [Member] | The Credit Agreement [Member] | Secured Overnight Financing Rate (SOFR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate			2%
The Lenders [Member] | The Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity							25,000
The Lenders [Member] | The Credit Agreement [Member] | Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity							10,000
The Lenders [Member] | The Credit Agreement [Member] | Swingline Loan Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity							10,000
The Lenders [Member] | Term Loan [Member] | The Credit Agreement [Member]
Long-term Debt, Gross							$ 40,000

Note 7 - Long-term Debt - Break

Note 7 - Long-term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Less: unamortized deferred financing costs	$ (630)	$ (840)
Total debt	38,743	46,824
Less: current portion of long-term debt	(3,750)	(4,091)
Current unamortized deferred financing costs	280	280
Long-term debt	35,273	43,013
Term Loan [Member]
Long-term debt, gross	31,473	34,814
Line of Credit [Member]
Long-term debt, gross	$ 7,900	$ 12,850

Note 8 - Derivatives (Details T

Note 8 - Derivatives (Details Textual) $ in Thousands	Sep. 30, 2023 USD ($)
The Credit Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Interest Rate Swap [Member]
Derivative, Notional Amount	$ 28,847

Note 8 - Derivatives - Derivati

Note 8 - Derivatives - Derivative Instruments (Details) - Interest Rate Swap [Member] $ in Thousands	Sep. 30, 2023 USD ($)
Interest rate swap	$ 28,847
Interest rate swap	$ 126

Note 8 - Derivatives - The Effe

Note 8 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Amount of gain recognized in OCI on derivatives (effective portion)	$ 163		$ 198
Amounts reclassified from accumulated other comprehensive loss to interest expense	(46)		(72)
Total	$ 117	$ 0	$ 126	$ 0

Note 9 - Fair Value Measureme_3

Note 9 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] $ in Thousands	Sep. 30, 2023 USD ($)
Equity securities - common stock	$ 3,788
Interest Rate Swap [Member]
Derivative liabilities	126
Fair Value, Inputs, Level 1 [Member]
Equity securities - common stock	3,788
Fair Value, Inputs, Level 1 [Member] | Interest Rate Swap [Member]
Derivative liabilities	0
Fair Value, Inputs, Level 2 [Member]
Equity securities - common stock	0
Fair Value, Inputs, Level 2 [Member] | Interest Rate Swap [Member]
Derivative liabilities	126
Fair Value, Inputs, Level 3 [Member]
Equity securities - common stock	0
Fair Value, Inputs, Level 3 [Member] | Interest Rate Swap [Member]
Derivative liabilities	$ 0

Note 10 - Capital Stock and S_3

Note 10 - Capital Stock and Stock-based Compensation (Details Textual) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 6
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 8 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 2.61

Note 10 - Capital Stock and S_4

Note 10 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Balance at December 31, 2022 (in shares) | shares	1,238,776
Balance at December 31, 2022 (in dollars per share) | $ / shares	$ 3.15
Options, Granted in Period (in shares) | shares	0
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0
Options, exercised (in shares) | shares	(213,644)
Options, exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 2.38
Options, Cancelled / Forfeited in Period (in shares) | shares	(101,065)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 2.47
Balance at September 30, 2023 (in shares) | shares	924,067
Balance at September 30, 2023 (in dollars per share) | $ / shares	$ 3.37
Restricted Stock Units (RSUs) [Member]
Balance at December 31, 2022 (in shares) | shares	1,093,801
Balance at December 31, 2022 (in dollars per share) | $ / shares	$ 3.94
Restricted Stock Units, Granted in Period (in shares) | shares	1,306,445
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 2.82
Restricted Stock Units, Vested in Period (in shares) | shares	(295,531)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 2.97
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) | shares	(86,440)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 3.9
Balance at September 30, 2023 (in shares) | shares	2,018,275
Balance at September 30, 2023 (in dollars per share) | $ / shares	$ 3.36
Market Condition Restricted Stock Units [Member]
Balance at December 31, 2022 (in shares) | shares	646,235
Balance at December 31, 2022 (in dollars per share) | $ / shares	$ 4.51
Restricted Stock Units, Granted in Period (in shares) | shares	558,958
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 2.61
Restricted Stock Units, Vested in Period (in shares) | shares	(115,976)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 2.98
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) | shares	(87,138)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) | $ / shares	$ 4.64
Balance at September 30, 2023 (in shares) | shares	1,002,079
Balance at September 30, 2023 (in dollars per share) | $ / shares	$ 3.62

Note 10 - Capital Stock and S_5

Note 10 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based compensation	$ 1,363	$ 1,139	$ 3,618	$ 3,401
Continuing Operations [Member] | Cost of Sales [Member]
Share-based compensation	58	0	222	88
Continuing Operations [Member] | Selling and Marketing Expense [Member]
Share-based compensation	193	147	533	493
Continuing Operations [Member] | General and Administrative Expense [Member]
Share-based compensation	1,012	919	2,585	2,633
Continuing Operations [Member] | Research and Development Expense [Member]
Share-based compensation	$ 100	$ 73	$ 278	$ 187

Note 10 - Capital Stock and S_6

Note 10 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member] - Share-Based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2023
Volatility	56.80%
Risk-free interest rate	4.60%
Correlation coefficient	41.70%
Dividend yield	0%

Note 10 - Capital Stock and S_7

Note 10 - Capital Stock and Stock-based Compensation - Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net loss available to common stockholders	$ (1,239)	$ (3,405)	$ (1,597)	$ (7,850)
Weighted average shares outstanding - basic (in shares)	42,688	41,637	42,345	41,353
Dilutive effect of equity awards (in shares)	0	0	0	0
Weighted average shares outstanding - diluted (in shares)	42,688	41,637	42,345	41,353
Basic loss per share (in dollars per share)	$ (0.03)	$ (0.08)	$ (0.04)	$ (0.19)
Diluted loss per share (in dollars per share)	$ (0.03)	$ (0.08)	$ (0.04)	$ (0.19)
Shares excluded from diluted loss per share due to their anti-dilutive effect (in shares)	3,952	3,594	3,847	3,676

Note 11 - Revenues (Details Tex

Note 11 - Revenues (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Contract with Customer, Liability, Revenue Recognized	$ 1	$ 0.8	$ 2.3	$ 2.1

Note 11 - Revenues - Disaggrega

Note 11 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 25,363	$ 26,922	$ 84,097	$ 84,908
Instruments, Equipment, Software, and Accessories [Member]
Revenues	23,500	25,705	79,261	81,008
Service, Maintenance, and Warranty Contracts [Member]
Revenues	$ 1,863	$ 1,217	$ 4,836	$ 3,900

Note 11 - Revenues - Revenue by

Note 11 - Revenues - Revenue by Geographic Destination (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total revenues	$ 25,363	$ 26,922	$ 84,097	$ 84,908
UNITED STATES
Total revenues	12,017	11,511	36,655	38,278
Europe [Member]
Total revenues	7,063	7,344	23,836	22,361
Greater China [Member]
Total revenues	3,489	4,497	13,824	11,624
Rest of the World [Member]
Total revenues	$ 2,794	$ 3,570	$ 9,782	$ 12,645

Note 11 - Revenues - Deferred R

Note 11 - Revenues - Deferred Revenue (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Deferred revenue	$ 4,005		$ 3,370
Deferred revenue, change	$ 635	$ (551)
Deferred revenue, % change	19%
Service [Member]
Deferred revenue	$ 2,234		1,530
Deferred revenue, change	$ 704
Deferred revenue, % change	46%
Customer Advances [Member]
Deferred revenue	$ 1,771		$ 1,840
Deferred revenue, change	$ (69)
Deferred revenue, % change	(4.00%)

Note 11 - Revenues - Warranties

Note 11 - Revenues - Warranties (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Balance	$ 191	$ 136
Provision for bad debts	9	103
Charge-offs and other	(56)	(60)
Balance	$ 144	$ 179

Note 12 - Income Tax (Details T

Note 12 - Income Tax (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Expense (Benefit)	$ 677	$ (1,285)	$ 144	$ (437)
Effective Income Tax Rate Reconciliation, Percent	(120.20%)	27.40%	(9.90%)	5.30%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingent Liabilities (Details Textual) $ in Thousands	Sep. 30, 2023 USD ($)
Director [Member] | Indemnification Agreements [Member]
Liability for Contingent Indemnification Obligations	$ 0

Note 14 - Litigation Settleme_2

Note 14 - Litigation Settlement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended			9 Months Ended		12 Months Ended
	Apr. 06, 2023	Jun. 10, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2022	Mar. 31, 2022
Loss Contingency, Estimate of Possible Loss				$ 200			$ 200
Litigation Settlement, Expense			$ 0	(544)		$ 0	(233)
Equity Securities, FV-NI, Unrealized Gain (Loss)			$ 1,208	0		$ (373)	0
Harvard Apparatus Regenerative Technology, Inc. (“HART”) [Member]
Investment Owned, Balance, Shares (in shares)			706,626			706,626
Investment Owned, Fair Value			$ 3,800			$ 3,800
Equity Securities, FV-NI, Unrealized Gain (Loss)			$ 1,200			$ (400)
Biostage [Member] | Private Placement [Member]
Conversion of Stock, Amount Issued	$ 6,000
Shares Issued, Price Per Share (in dollars per share)	$ 6
Series E Preferred Stock in Biostage [Member]
Equity Securities without Readily Determinable Fair Value, Amount					$ 3,900
Preferred Stock, Book Value, Inclusive of Accrued Dividends									$ 4,000
Convertible Preferred Stock [Member] | Biostage [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 6
Case in Suffolk Superior Court [Member]
Loss Contingency, Estimate of Possible Loss										$ 5,200
Litigation Settlement, Expense					$ (4,900)			$ 300
Case in Suffolk Superior Court [Member] | Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Issued For Settlement (in shares)		4,000
Stock Issued During Period, Value, Issued for Settlement		$ 4,000
Estimated Litigation Liability				$ 500			$ 500

Note 15 - Product Line Dispos_2

Note 15 - Product Line Disposition (Details Textual) - USD ($) $ in Thousands		9 Months Ended
	Feb. 17, 2023	Sep. 30, 2023	Sep. 30, 2022
Gain (Loss) on Disposition of Business		$ 403	$ 0
Hoefer Product Line [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 500
Disposal Group, Including Discontinued Operation, Assets	100
Gain (Loss) on Disposition of Business	$ 400

Note 16 - Financial Statement_2

Note 16 - Financial Statement Reclassifications (Details Textual) - Revision of Prior Period, Error Correction, Adjustment [Member] - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	$ 5.4	$ 5.1
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (5.4)	$ (5.1)